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 The aim of this project was to identify genetic variants that may influence the risk and 
progression of sarcoma through targeted genotyping of HSPA9 gene. It is important to look at 
genetic variants in DNA samples because if a variant is determined to be more likely than 
another, a screening for the particular variant can be done to identify a patient’s risk of sarcoma.  
The study population was sarcoma patients from the International Sarcoma Kindred Study. 
These patients had no mutations in p53 or MDM2.  Genotyping data from the HapMap project 
(hapmap.org) for HSPA9 was used to identify the polymorphisms needed to tag the entire region.  
In order to genotype the DNA sample, KASP reagents (KBioSciences, UK) were used. KASP 
uses a two-set PCR process. Allele specific primers are used to preferentially amplify each allele 
of a given SNP.  The specific genetic variations of HSPA9 in sarcoma patient DNA samples with 
no mutations in p53 or MDM2 amplification are not more or less likely to occur than in DNA 
samples with the mutation or amplification.  If continued research can show that MDM2 is not 
amplified, but activated through other mechanisms such as the interaction between 
polymorphisms of mitochondrial genes, p53, or MDM2, we can propose anti-MDM2 therapies to 
the patients with these polymorphisms.  
Introduction 
 
Identifiying genetic variants that may influence the risk and progression of sarcoma through 
targeted genotyping of HSPA9 gene is important because looking at genetic variants in DNA 
samples and significant relationships of variants may help produce a screening for the particular 
variant that can be done to identify a patient’s risk of sarcoma. A strong candidate biological 
pathway in cancer susceptibility is the regulation of growth arrest and/or apoptosis in the stressed 
or damaged cell (Cox et. al., 2007). The tumor suppressor gene p53 and MDM2 are essential in 
cell apoptosis. A malfunctioning of p53 or MDM2 amplification will inhibit cell death of a 
cancerous cell. In normal human cells, the p53 protein has a pivotal role in the regulation of 
growth arrest and apoptosis when DNA is damaged. In 60% of human cancers, p53 malfunctions 
and cannot bind to DNA to transcribe downstream genes that initiate apoptosis (Vaseva and 
Moll, 2008). Many patients do not have mutations in p53 or MDM2 amplification that cause the 
malfunction in cancer cell, so the target DNA samples were sarcoma patient without p53 or 
MDM2 amplification. The HSPA9 gene encodes for mortalin. Mortalin has an important role in 
this pathway because in conditions of high stress, some cancer cell lines have been seen to have 
an overexpression of mortalin. This over expression causes a binding of mortalin and p53. Once 
p53 is bound to mortalin, it cannot be used as a checkpoint in the cell cycle to induce apoptosis 
of cancerous cells. Many variants in the gene for mortalin have been associated with Parkinson’s 
Disease (Lu 2011, Burbulla 2011).   
 Dr. David Cox has performed research on the polymorphisms of tumor suppressor gene, 
p53, in relation to polymorphisms in MDM2, which causes p53 to become biologically active 
through processing (Cox et.al. 2007). Mutations in the tumor suppressor gene p53 and 
amplification of the MDM2 gene occur in many sarcomas, but these mutations and 
amplifications are not detected in all patients. Therefore, a hypothesis has been proposed that 
patients without p53 mutations and MDM2 amplifications may have germ line variants or cryptic 
mutations in genes related to p53, MDM2, and mitochondria-mediated apoptosis that are 
responsible for their sarcoma. SNP tagging can be done to identify polymorphisms that may 
influence sarcoma risk and progression. The null hypothesis is that there is no association 
between polymorphisms in HSPA9 and sarcoma. 
 
Material and Methods 
Study Population 
 The study population were sarcoma patients from the International Sarcoma Kindred 
Study (ISKS). Patients are recruited by hospitals around the world. DNA samples are both kept 
locally at each national collaborating center and centralized at the main study center in Australia. 
DNA from blood samples and tumors is available. Tumors are studied for p53 mutations and 
MDM2 amplifications. DNA samples were requested from the main study center in Australia. 
There were 53 patients DNA samples and 29 control DNA samples. The 53 patients were cases 
that did not have mutations in p53 or MDM2 amplifications. The 29 control samples were 
positive for the mutation and amplification. 
SNP Tagging 
 In order to tag the single nucleotide polymorphisms, the desired genetic variants had to 
be determined. Genotyping data from the HapMap project (hapmap.org) for HSPA9 was used to 
identify the polymorphisms needed to tag the entire region. HapMap is a catalog of common 
genetic variants that occur in human beings. It describes what these variants are, where they 
occur in our DNA, and how they are distributed among people within populations and among 
populations in different parts of the world. HSPA9 is located on chromosome 5. The gene starts 
at 137890000 and ends at 137921318. By inputting the location of the gene, HapMap provides a 
list of all relevant SNPs.  
 The SNP information on HapMap was extracted and uploaded to the Haploview program. 
The Tagger functionality of the Haploview program was used to select the tagSNPS. A tagSNP 
respresents single nucleotide polymorphisms in a region of the genome with high linkage 
disequilibrium. The group of SNPs that a tagSNP represents is called a haplotype. This makes it 
possible to identify genetic variation and association to phenotypes without genotyping every 
SNP in a chromosomal region. After using this program with the data from the HapMap project 
four tagSNPs were chosen for HSPA9. The tagSNPs were rs256008, rs256001, rs1042665 and 




Figure 1. Representation of the location of the gene HSPA9 on chromosome 5. This image also 
illustrates the number of SNPs at the region of the chromosome within HSPA9. This information 
was exported and the tagSNPs were determined. The four tagSNPs represent all of the SNPs at 
this particular location (Hapmap.org). 
 Figure 2. Determination of TagSNPs. SNPs inherited together are complied into haplotypes. 
TagSNPs within haplotypes are identified that uniquely identify those haplotypes. Haplotype of 
individual can then be determined (Hapmap.org).  
 
Genotyping 
 In order to genotype the DNA sample, KASP reagents (KBioSciences, UK) were used. 
KASP uses a two-set PCR process.  Allele specific primers are used to preferentially amplify 
each allele of a given SNP. These primers have a sequence tag that is engineered to expand a 
cassette tagged with one of two fluorophores, allowing for the detection of the alleles present. 
PCR reactions will be carried out in real-time on a StepOne Plus thermocycler, followed by an 
allele discrimination step at the end of PCR cycling.  
Analysis 
Once this was done for all four of the tagSNPs with all of the DNA samples, the genotypes were 
able to be determined. After genotypes were determined, the Haplo.stats package for R was used. 
This program is able to statistically determine haplotype frequencies of potential haplotypes in 
the gene and calculate odd ratios to determine the likelihood of each haplotype. 
Results 
Genotype Data 
rs256008 Allele 1/Allele1 Allele1/Allele2 Allele2/Allele2 Total 
Cases 0 5 (10%) 45 (90%) 50 
Control 0 0 (0) 27 (100) 27 
Total 0 5 72 77 
rs256001 Allele 1/Allele1 Allele1/Allele2 Allele2/Allele2 Total 
Cases 43 (89.6%) 5 (10.4%) 0 48 
Control 27 (100) 0 (0) 0 27 
Total 70 5 0 75 
rs1042665 Allele 1/Allele1 Allele1/Allele2 Allele2/Allele2 Total 
Cases 1 (2%) 21(43%) 27 (55%) 49 
Control 4 (14.8%) 12 (44.4%) 11 (40.7%) 27 
Total 5 33 38 76 
rs11740501 Allele 1/Allele1 Allele1/Allele2 Allele2/Allele2 Total 
Cases 31 (60.8%) 17 (33.3%) 3 (5.9%) 51 
Control 19 (65.6%) 9 (31%) 1 (3.4%) 29 
Total 50 26 4 80 
 
Table 1. Number of patients for homozygous for allele1, allele 2 or heterozygous for the 
tagSNPs rs256008, rs256001, rs1042665, rs11740501. 
 
 After the DNA samples were added to the KASP reagents and SNP primers, the 
genotypes at the SNP locations were determined. For the rs256008, no cases or controls were 
homozygous for allele 1, five cases were heterozygous, and 45 cases and 27 controls were 
homozygous for allele 2. For rs256001, 43 cases and 27 controls were homozygous for allele 1, 5 
cases were heterozygous, and no cases or controls were homozygous for allele 2. For rs1042665, 
1 case and 4 controls were homozygous for allele 1, 21 cases and 12 controls were heterozygous, 
and 27 cases and 11 controls were homozygous for allele 2. For rs11740501, 31 cases and 19 
controls were homozygous for allele 1, 17 cases and 9 controls were heterozygous, and 3 cases 
and 1 control were homozygous for allele 2. It was necessary to determine the genotypes of the 
in order to configure haplotype frequencies. 
Haplotype Data 
Table 2. Haplotype frequency and likelihood of occurrence.  
 With the genotype information, the haplotypes were determined as well as the haplotype 
frequencies using the Haplo.stats package in R.  With the genotypes determined, three 
haplotypes were statistically configured. Each haplotype represents a group of SNPs that may be 
associated. Each of the haplotypes contain different SNPs based on the tagSNPs that were 
genotyped. Based on Table 2 the odds ratio for all three of the haplotypes include one when 
adding the confidence intervals. The haplotype frequency for haplotype 1 is 0.47 when 
comparing the case and control. The haplotype frequency for haplotype 1 for just the case is 
0.49. The haplotype frequency for haplotype 1 for the control is 0.44. The haplotype frequency 
for haplotype 2 is 0.21. The haplotype frequency of haplotype 3 is 0.28. 
Haplotypes Hap.freq Case hap.freq Control hap.freq Odds Ratio Confidence Intervals 
1 0.471757 24.9 (0.4886) 12.81 (0.44201) 1 1 
2 0.2125 11.5 (0.22549) 5.5 (0.18966) 0.985 0.39875, 2.4332 
3 0.283401 12 (0.23504) 3.93 (0.36834) 1.85 0.76716, 4.4614 
Discussion 
 Based on the results, all three of the odds ratios, with confidence intervals, included one. 
If an odds ratio is one the data set is not statistically significant because including one means that 
there is not a haplotype that is more or less likely to be a haplotype in a case than in a control. 
This exhibits that the specific genetic variations of HSPA9 in sarcoma patient DNA samples with 
no mutations in p53 or MDM2 amplification are not more or less likely to occur than in DNA 
samples with the mutation or amplification. This information is important because describes the 
relationship of the genetic variations in HSPA9 with the risk of sarcoma.  
 To continue the exploration of genetic variations in this biological pathway, it is 
important to now look at the genetic variations in p53 and MDM2 and their association with the 
risk and progression of sarcoma.  This is important because there is little known about the 
mechanisms behind what causes a risk for sarcomas, with the exception of certain translocation 
mutations. By doing research on SNPs of selected gene sequences we can advance the field by 
providing more mechanistic descriptions of the biology behind sarcoma tumorgenesis. Today, 
only patients that have amplification of the MDM2 gene can be treated with anti-MDM2 
therapies. If continue research can show that MDM2 is implicated in sarcomas, and not 
amplified, but activated through other mechanisms such as the interaction between 
polymorphisms of mitochondria, p53, MDM2 or we can propose anti-MDM2 therapies to the 
patients with these polymorphisms. 
 In order to do so, the next objective would be to use standard statistical modeling to 
examine statistical interactions between the Arg72Pro allele of p53 and the G309T 
polymorphism in MDM2. These include the Likelihood Ratio Test, which compares the model 
that includes only main effects for the two polymorphisms to the model containing the main 
effects as well as an interaction term. This test should be analogous to the Wald test for 
interaction, which is simply the p-value of the interaction term in the latter model. 
 The mitochondrial genome also encodes for a number of genes, mainly proteins that are 
involved in the electron transport chain. Reactive oxygen species (ROS) generated through the 
electron transport chain can lead to DNA damage, initiating a feedback loop that, if unchecked, 
will lead eventually to apoptosis. Humanin, encoded by a mitochondrial 16SRNA, can block the 
translocation of Bax to the mitochondrial membrane, blocking the release of cytochrome C 
leading to apoptosis (Guo 2003). This would be an area of interest for further research. To 
understand the significance phylogenetic trees can then be used to describe populations based on 
their mitochondrial polymorphisms. The distribution of subjects in trees based on different 
phenotypes (i.e. different forms of sarcoma, p53 or MDM2 polymorphisms) can be compared 
across trees, in order to identify potential associations between mitochondrial variants and these 
phenotypes. 
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